scholarly article | Q13442814 |
P50 | author | Ralph A. DeFronzo | Q58689309 |
P2860 | cites work | Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial | Q46834147 |
The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes | Q46849871 | ||
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study | Q46860931 | ||
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years | Q46870991 | ||
Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. | Q46881268 | ||
Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial | Q46936072 | ||
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin | Q46981921 | ||
Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus | Q47205801 | ||
Role of brain insulin receptor in control of body weight and reproduction | Q47229086 | ||
Altered hypothalamic function in response to glucose ingestion in obese humans | Q48116701 | ||
Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes | Q22241283 | ||
The blooming of the French lilac | Q22241897 | ||
Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 | ||
The fundamental drivers of the obesity epidemic | Q22242406 | ||
Insulin signalling and the regulation of glucose and lipid metabolism | Q24292020 | ||
Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator | Q24294798 | ||
Mechanism of free fatty acid-induced insulin resistance in humans | Q24562106 | ||
Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle | Q24564824 | ||
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis | Q24655066 | ||
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 | Q24679555 | ||
Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents | Q24812499 | ||
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 | Q28131760 | ||
The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus | Q28190307 | ||
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes | Q28193039 | ||
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
Central melanocortin receptors regulate insulin action | Q28360753 | ||
Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes | Q28369463 | ||
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes | Q29547229 | ||
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
Banting lecture 1988. Role of insulin resistance in human disease | Q29547283 | ||
Central nervous system control of food intake | Q29547439 | ||
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes | Q29614589 | ||
Critical nodes in signalling pathways: insights into insulin action | Q29614735 | ||
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes | Q29614878 | ||
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study | Q30700439 | ||
DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells | Q31833471 | ||
Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. | Q51024670 | ||
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. | Q51470916 | ||
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. | Q51480151 | ||
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
The effect of pioglitazone on the liver: role of adiponectin. | Q51488911 | ||
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. | Q51551544 | ||
Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. | Q51554321 | ||
Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. | Q51554684 | ||
Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. | Q51562946 | ||
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. | Q51567209 | ||
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. | Q51570043 | ||
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. | Q51570046 | ||
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. | Q51571115 | ||
Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. | Q51578788 | ||
Decreased Insulin Secretion and Increased Insulin Resistance Are Independently Related to the 7-Year Risk of NIDDM in Mexican-Americans | Q51584502 | ||
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. | Q51592563 | ||
The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents | Q51603248 | ||
Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. | Q51606513 | ||
Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. | Q51613168 | ||
Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. | Q51614068 | ||
Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. | Q51618277 | ||
The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. | Q51619627 | ||
Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. | Q51620602 | ||
Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. | Q51621447 | ||
The natural history of impaired glucose tolerance in the Pima Indians. | Q51623599 | ||
Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. | Q51623792 | ||
Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. | Q51627070 | ||
Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. | Q51628168 | ||
Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. | Q51629772 | ||
Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. | Q51636513 | ||
The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. | Q51639006 | ||
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes | Q36764031 | ||
The insulin resistance syndrome: physiological considerations | Q36806509 | ||
Exenatide can reduce glucose independent of islet hormones or gastric emptying | Q36846123 | ||
Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial | Q36972810 | ||
Effect of fatty acids on glucose production and utilization in man | Q36992461 | ||
Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus | Q37004187 | ||
Insulin Binding to Monocytes and Insulin Action in Human Obesity, Starvation, and Refeeding | Q37030221 | ||
Insulin Sensitivity and Insulin Binding to Monocytes in Maturity-Onset Diabetes | Q37038173 | ||
Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance | Q37066869 | ||
Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle | Q37175187 | ||
Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands | Q37376927 | ||
Glucose metabolism in obesity and type 2 diabetes | Q37443341 | ||
Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus | Q38674648 | ||
Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach | Q38723548 | ||
Cardiovascular morbidity and mortality associated with the metabolic syndrome | Q39513407 | ||
Lack of a gastrointestinal mediator of insulin action in maturity-onset diabetes | Q39516489 | ||
Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 | ||
Physical training and insulin sensitivity. | Q39736549 | ||
Regulation of hepatic glucose metabolism in humans | Q39764293 | ||
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes | Q40137823 | ||
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance | Q40177903 | ||
Lifestyle intervention for pre-diabetic neuropathy | Q40321365 | ||
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus | Q40342100 | ||
Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. | Q40452210 | ||
Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells | Q40488458 | ||
Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells | Q40747693 | ||
Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). | Q40799734 | ||
Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. | Q41015653 | ||
The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus | Q41176971 | ||
Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase | Q41330413 | ||
Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide | Q41394581 | ||
Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog | Q42140416 | ||
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects | Q42436041 | ||
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo | Q42437607 | ||
Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes | Q42441787 | ||
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes | Q42450726 | ||
Ceramide content is increased in skeletal muscle from obese insulin-resistant humans | Q42454790 | ||
Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes | Q42489695 | ||
Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. | Q42506332 | ||
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats | Q42545275 | ||
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study | Q42691702 | ||
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | Q43584208 | ||
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 | ||
Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats | Q43644419 | ||
Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes | Q43687850 | ||
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes | Q43778779 | ||
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | Q31976463 | ||
Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development | Q31979634 | ||
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year | Q33220335 | ||
Insulin signaling in the arterial wall | Q33694779 | ||
Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver | Q33799804 | ||
Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity | Q33834971 | ||
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial | Q33844615 | ||
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
Fuel selection in human skeletal muscle in insulin resistance: a reexamination | Q33975119 | ||
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. | Q34126257 | ||
Glucose clamp technique: a method for quantifying insulin secretion and resistance | Q34191986 | ||
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach | Q34294997 | ||
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program | Q34312885 | ||
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. | Q34327135 | ||
Thiazolidinediones | Q34346862 | ||
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
The biology of incretin hormones | Q34499706 | ||
Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions | Q34527799 | ||
Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus | Q34541876 | ||
Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy | Q34555883 | ||
Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes | Q34556238 | ||
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance | Q34577169 | ||
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects | Q34616729 | ||
Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. | Q34655571 | ||
The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes | Q34655580 | ||
Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus | Q34669998 | ||
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes | Q34692143 | ||
Central insulin action in energy and glucose homeostasis | Q34698802 | ||
Islet beta cell failure in type 2 diabetes | Q34698810 | ||
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity | Q34760010 | ||
Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation | Q43778798 | ||
Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans | Q43806846 | ||
Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians | Q43850960 | ||
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients | Q43855921 | ||
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects | Q43867557 | ||
Lipotoxicity in human pancreatic islets and the protective effect of metformin | Q43869352 | ||
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). | Q43869405 | ||
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study | Q43959543 | ||
Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. | Q43972538 | ||
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle | Q43990155 | ||
Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats | Q44001034 | ||
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients | Q44018167 | ||
Effect of increased free fatty acid supply on glucose metabolism and skeletal muscle glycogen synthase activity in normal man | Q44026790 | ||
Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha | Q44043178 | ||
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study | Q44043328 | ||
Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition | Q44114881 | ||
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women | Q44114894 | ||
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. | Q44117925 | ||
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes | Q44155554 | ||
Insulin levels and the natural history of glucose intolerance in Nauruans | Q44177121 | ||
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics | Q44183858 | ||
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes | Q44231053 | ||
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets | Q44320631 | ||
Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes | Q44452815 | ||
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes | Q44452988 | ||
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients | Q44527041 | ||
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients | Q44631767 | ||
Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. | Q44660894 | ||
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study | Q44686996 | ||
Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. | Q44687269 | ||
Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-ce | Q44786873 | ||
Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes | Q44873148 | ||
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes | Q44883028 | ||
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study | Q45074002 | ||
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 | ||
Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet | Q45124377 | ||
Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects | Q45161422 | ||
Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans | Q45168872 | ||
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes | Q45199153 | ||
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes | Q45285687 | ||
The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance | Q45924710 | ||
Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance | Q46126827 | ||
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes | Q46226028 | ||
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes | Q46486537 | ||
Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance | Q46507502 | ||
Dose-response effect of elevated plasma free fatty acid on insulin signaling | Q46513253 | ||
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients | Q46598346 | ||
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes | Q46707421 | ||
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients | Q46774705 | ||
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics. | Q34779949 | ||
Wnt signaling: relevance to beta-cell biology and diabetes | Q34858330 | ||
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus | Q34876148 | ||
Spontaneous and experimental human obesity: Effects of diet and adipose cell size on lipolysis and lipogenesis | Q34979019 | ||
Aging and insulin secretion | Q35027205 | ||
Metabolic and molecular basis of insulin resistance | Q35148800 | ||
Studies of pancreatic alpha cell function in normal and diabetic subjects | Q35576866 | ||
Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism | Q35578164 | ||
31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus | Q35600062 | ||
Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study | Q35606593 | ||
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats | Q35654399 | ||
Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism | Q35818094 | ||
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans | Q35844598 | ||
Pathogenesis of type 2 diabetes mellitus | Q35861736 | ||
Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size | Q35900499 | ||
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes | Q35916172 | ||
Molecular mechanisms of insulin resistance that impact cardiovascular biology | Q35927757 | ||
Rosiglitazone RECORD study: glucose control outcomes at 18 months | Q35987411 | ||
Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange | Q35996659 | ||
Dysfunctional fat cells, lipotoxicity and type 2 diabetes | Q36202576 | ||
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. | Q36369954 | ||
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review | Q36396145 | ||
Insulin resistance and improvements in signal transduction | Q36452535 | ||
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose | Q36462545 | ||
The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program | Q36496751 | ||
Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin | Q36549287 | ||
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q36549321 | ||
Incretins and the development of type 2 diabetes | Q36560963 | ||
Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study | Q46774747 | ||
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
Physiological and molecular determinants of insulin action in the baboon. | Q46823836 | ||
Diagnosis and classification of diabetes mellitus | Q80423340 | ||
Genes and type 2 diabetes mellitus | Q81637160 | ||
Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal | Q51642223 | ||
Effect of age on glucose tolerance, insulin secretion, and in vivo insulin action. | Q51649878 | ||
Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. | Q51660630 | ||
ROLES OF INSULIN AND GROWTH HORMONE, BASED ON STUDIES OF FOREARM METABOLISM IN MAN | Q51692542 | ||
Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. | Q52575906 | ||
Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. | Q54332121 | ||
Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. | Q54346849 | ||
Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. | Q54383566 | ||
Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. | Q55066500 | ||
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | Q56914456 | ||
Transcription Factor TCF7L2 Genetic Study in the French Population: Expression in Human -Cells and Adipose Tissue and Strong Association With Type 2 Diabetes | Q57244236 | ||
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution | Q57278407 | ||
The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose | Q57504429 | ||
Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients | Q58449883 | ||
Lipid Infusion Decreases the Expression of Nuclear Encoded Mitochondrial Genes and Increases the Expression of Extracellular Matrix Genes in Human Skeletal Muscle | Q58451168 | ||
Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals | Q60227968 | ||
Ability of Alternative Indices of Insulin Sensitivity to Predict Cardiovascular Risk | Q60692503 | ||
A second-generation genetic linkage map of the baboon (Papio hamadryas) genome | Q61450418 | ||
Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study | Q67521964 | ||
The disposal of an oral glucose load in patients with non-insulin-dependent diabetes | Q68123673 | ||
Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity | Q68197320 | ||
Glucose toxicity | Q68519957 | ||
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 | ||
Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus | Q68917267 | ||
Impaired insulin secretion associated with near normoglycemia. Study in normal rats with 96-h in vivo glucose infusions | Q68935151 | ||
Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets | Q69502077 | ||
Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets | Q69522381 | ||
Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man | Q70237412 | ||
Counterregulatory Hormone Release and Glucose Recovery After Hypoglycemia in Non-insulin-dependent Diabetic Patients | Q70300852 | ||
Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects | Q70531560 | ||
Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM | Q71097305 | ||
Effect of long chain triglyceride infusion on glucose metabolism in man | Q71447509 | ||
Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle | Q71553004 | ||
Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats | Q72324013 | ||
Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats | Q73430341 | ||
PGC-1alpha at the crossroads of type 2 diabetes | Q73588702 | ||
Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance | Q74011817 | ||
Effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo | Q74065230 | ||
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group | Q74432253 | ||
EFFECTS OF FAT INFUSION ON GLUCOSE TOLERANCE AND INSULIN PLASMA LEVELS | Q76752574 | ||
Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade | Q77795070 | ||
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study | Q79678578 | ||
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients | Q79782845 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | type 2 diabetes | Q3025883 |
P304 | page(s) | 773-795 | |
P577 | publication date | 2009-04-01 | |
P1433 | published in | Diabetes | Q895262 |
P1476 | title | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | |
P478 | volume | 58 |
Q90549493 | "H" for Heterogeneity in the Algorithm for Type 2 Diabetes Management |
Q92151256 | 'Beauty and the beast' in infection: How immune-endocrine interactions regulate systemic metabolism in the context of infection |
Q53804491 | 1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice. |
Q92025092 | 17Beta-estradiol Stimulates Glucose Uptake Through Estrogen Receptor and AMP-activated Protein Kinase Activation in C2C12 Myotubes (Korean J Obes 2016;25:190-6) |
Q47215070 | 4',6-Dimethoxyisoflavone-7-O-β-D-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor α (PPARα) agonist in mouse hepatocytes. |
Q35336944 | A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections |
Q33541007 | A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control |
Q34161881 | A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor |
Q92395803 | A State-of-the-Science Review of Arsenic's Effects on Glucose Homeostasis in Experimental Models |
Q34264365 | A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus |
Q26799389 | A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond |
Q33833281 | A comparison of three (67/68)Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator |
Q30424086 | A confirmatory factor analysis of the metabolic syndrome in adolescents: an examination of sex and racial/ethnic differences |
Q42280003 | A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection |
Q83176026 | A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes |
Q51332810 | A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. |
Q35072374 | A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects |
Q41922145 | A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control |
Q91841793 | A gene expression network analysis of the pancreatic islets from lean and obese mice identifies complement 1q like-3 secreted protein as a regulator of β-cell function |
Q34308071 | A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans |
Q37890777 | A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition |
Q35578281 | A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study |
Q51386060 | A novel surrogate index for hepatic insulin resistance. |
Q55116421 | A periodontal disease care program for patients with type 2 diabetes: A randomized controlled trial. |
Q34374321 | A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus |
Q42846868 | A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin |
Q37965612 | A review of gliptins in 2011. |
Q35157954 | A review of the treatment of type 2 diabetes in children |
Q53559962 | Abrogation of adenosine A1 receptor signalling improves metabolic regulation in mice by modulating oxidative stress and inflammatory responses. |
Q57145191 | Acanthosis nigricans in the knuckles: An early, accessible, straightforward, and sensitive clinical tool to predict insulin resistance |
Q33731729 | Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes |
Q51357717 | Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. |
Q37818234 | Add-on therapies to metformin for type 2 diabetes |
Q36546914 | Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy |
Q37785451 | Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care |
Q26830274 | Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development |
Q28068120 | Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy |
Q90221587 | Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease |
Q93222250 | Adipose Tissue Insulin Resistance in Youth on the Spectrum From Normal Weight to Obese and From Normal Glucose Tolerance to Impaired Glucose Tolerance to Type 2 Diabetes |
Q50185850 | Adipose tissue: The dysfunctional adipocyte - a cancer cell's best friend. |
Q35711564 | Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy |
Q42858950 | Adrenergic India: Managing its diabetes |
Q38072616 | Advances in pharmacologic therapies for type 2 diabetes |
Q36327944 | Advances in the treatment of prediabetes |
Q26746220 | Advances in the treatment of type 2 diabetes: impact of dulaglutide |
Q93046302 | Aerobic exercise training improves hepatic and muscle insulin sensitivity, but reduces splanchnic glucose uptake in obese humans with type 2 diabetes |
Q35059477 | Age trajectories of glycaemic traits in non-diabetic South Asian and white individuals: the Whitehall II cohort study. |
Q34252924 | Age-related impairment in insulin release: the essential role of β(2)-adrenergic receptor |
Q41860198 | Aging and insulin resistance: just say iNOS. |
Q35973271 | Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study |
Q51371120 | Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. |
Q28263483 | An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion |
Q53686961 | An In Ovo Model for Testing Insulin-mimetic Compounds. |
Q26749089 | An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass |
Q38972500 | An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus |
Q37661798 | An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes |
Q64935296 | Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus. |
Q47402416 | Androgen signaling expands β-cell mass in male rats and β-cell androgen receptor is degraded under high-glucose conditions. |
Q37391675 | Angiotensin II Promotes the Development of Carotid Atherosclerosis in Type 2 Diabetes Patients via Regulating the T Cells Activities: A Cohort Study |
Q28828825 | Anti-Diabetic Effect of Portulaca oleracea L. Polysaccharideandits Mechanism in Diabetic Rats |
Q36049831 | Antiaging gene Klotho enhances glucose-induced insulin secretion by up-regulating plasma membrane levels of TRPV2 in MIN6 β-cells |
Q92446097 | Antidiabetic Properties of Curcumin I: Evidence from In Vitro Studies |
Q92281989 | Antidiabetic Properties of Curcumin II: Evidence from In Vivo Studies |
Q64100894 | Antidiabetic Properties of Naringenin: A Citrus Fruit Polyphenol |
Q54599587 | Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. |
Q38219485 | Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy |
Q37198158 | Application of the Oral Minimal Model to Korean Subjects with Normal Glucose Tolerance and Type 2 Diabetes Mellitus |
Q90732416 | Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials |
Q55043860 | Are We Compensating for the Lack of Physical Activity in Our Diabetic Patients with Treatment Intensification? |
Q92421225 | Assessing and Managing the Metabolic Syndrome in Children and Adolescents |
Q33732627 | Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials |
Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
Q41111642 | Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study. |
Q37738299 | Association between Self-reported Snoring and Prediabetes among Adults Aged 40 Years and Older without Diabetes |
Q30358842 | Association between serum 25-hydroxyvitamin D and carotid atherosclerotic plaque in Chinese type 2 diabetic patients |
Q51384660 | Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. |
Q35932340 | Association of the Genetic Polymorphisms in Transcription Factor 7-Like 2 and Peroxisome Proliferator-Activated Receptors- γ 2 with Type 2 Diabetes Mellitus and is Interaction with Obesity Status in Emirati Population |
Q37721986 | Associations between dairy foods, diabetes, and metabolic health: potential mechanisms and future directions |
Q59813547 | Associations of Insulin Levels and Insulin Resistance With Urine Glucose Excretion Independent of Blood Glucose in Chinese Adults With Prediabetes and Newly Diagnosed Diabetes |
Q45070738 | Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness |
Q36163431 | Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass? |
Q51553915 | Bariatric surgery for diabetes: the International Diabetes Federation takes a position. |
Q34264630 | Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW |
Q64111064 | Beneficial Effects of Citrus Flavonoids on Cardiovascular and Metabolic Health |
Q33942058 | Beneficial effects of resistance exercise on glycemic control are not further improved by protein ingestion |
Q99408960 | Beta-aminoisobutyric acid is released by contracting human skeletal muscle and lowers insulin release from INS-1 832/3 cells by mediating mitochondrial energy metabolism |
Q42115230 | Betatrophin: A liver-derived hormone for the pancreatic β-cell proliferation |
Q26738696 | Beyond Diabetes: Does Obesity-Induced Oxidative Stress Drive the Aging Process? |
Q98178564 | Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes |
Q37404625 | Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications |
Q89999342 | Biomarkers for type 2 diabetes |
Q50454359 | Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. |
Q64299394 | Black African men with early type 2 diabetes have similar muscle, liver and adipose tissue insulin sensitivity to white European men despite lower visceral fat |
Q34620547 | Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes |
Q35153082 | Bromocriptine in type 2 diabetes mellitus |
Q34718312 | Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes |
Q35130696 | CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. |
Q91809508 | Calcium Signaling in ß-cell Physiology and Pathology: A Revisit |
Q38164682 | Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes |
Q38254252 | Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes |
Q38573559 | Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus |
Q39620719 | Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy? |
Q47849041 | Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? |
Q26752255 | Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? |
Q34383575 | Cardiovascular impact of drugs used in the treatment of diabetes |
Q54383946 | Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. |
Q34478412 | Castration-induced testosterone deficiency increases fasting glucose associated with hepatic and extra-hepatic insulin resistance in adult male rats |
Q42188498 | Causes of type 2 diabetes in China |
Q37826504 | Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia |
Q33801559 | Challenges in diagnosis and management of diabetes in the young |
Q90668590 | Changes in Plasma Protein Expression Indicative of Early Diet-induced Metabolic Disease in Male Pigs (Sus scrofa) |
Q37690772 | Changing the diagnosis criteria of type 2 diabetes in pregnancy: do the ends justify the means? |
Q33610676 | Changing the treatment paradigm for type 2 diabetes |
Q37193454 | Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes |
Q35556656 | Characterization of the ZDSD Rat: A Translational Model for the Study of Metabolic Syndrome and Type 2 Diabetes |
Q38129446 | Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes |
Q37949599 | Choosing a gliptin |
Q27318852 | Chronic consumption of farmed salmon containing persistent organic pollutants causes insulin resistance and obesity in mice |
Q34787903 | Chronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activity |
Q38074337 | Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae |
Q33959764 | Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals |
Q50143071 | Circadian Etiology of Type 2 Diabetes Mellitus. |
Q90371405 | Circadian clocks and insulin resistance |
Q58828952 | Circulating SFRP5 levels are elevated in drug-naïve recently diagnosed type 2 diabetic patients as compared with prediabetic subjects and controls |
Q92270005 | Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial |
Q39578134 | Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes |
Q38572961 | Clinical Management of Type 2 Diabetes Mellitus after Bariatric Surgery |
Q38971612 | Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. |
Q30238519 | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
Q37011769 | Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations |
Q58789064 | Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis |
Q35064831 | Clinical characteristics of OGTT-derived hepatic- and muscle insulin resistance in healthy young men. |
Q37979850 | Clinical considerations for the management of residual diabetes following bariatric surgery |
Q41476579 | Clinical implications of canagliflozin treatment in patients with type 2 diabetes |
Q34638128 | Clinical pharmacokinetics and pharmacodynamics of linagliptin. |
Q38468017 | Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus |
Q59136514 | Coffee and Type 2 Diabetes Risk |
Q38204541 | Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes |
Q51185982 | Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. |
Q34824247 | Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes |
Q51245398 | Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. |
Q26752294 | Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation |
Q38633198 | Combination therapy for type 2 diabetes: dapagliflozin plus metformin |
Q36303346 | Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin |
Q38640778 | Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences |
Q39255963 | Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor |
Q48320074 | Combination therapy with multiple oral hypoglycaemic agents together with short-term basal insulin in new-onset Type 2 diabetes mellitus with marked hyperglycaemia |
Q38014516 | Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings |
Q45841424 | Combining metabolomic non-targeted GC×GC-ToF-MS analysis and chemometric ASCA-based study of variances to assess dietary influence on type 2 diabetes development in a mouse model |
Q42419413 | Comment on: Tam et al. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 2012;35:1605-1610. |
Q41277849 | Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes |
Q91813042 | Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices |
Q33999894 | Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies |
Q58766494 | Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis |
Q36637980 | Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists. |
Q88117871 | Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial |
Q38167016 | Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes |
Q43045655 | Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes |
Q64125156 | Computation and application of tissue-specific gene set weights |
Q51702145 | Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. |
Q38452883 | Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options |
Q37606197 | Contribution of the serine kinase c-Jun N-terminal kinase (JNK) to oxidant-induced insulin resistance in isolated rat skeletal muscle |
Q37698362 | Cooperation between brain and islet in glucose homeostasis and diabetes |
Q50145776 | Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. |
Q83532321 | Could FFAR1 assist insulin secretion in type 2 diabetes? |
Q33662676 | Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist |
Q38866233 | Creatine supplementation and glycemic control: a systematic review |
Q36790184 | Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. |
Q84596471 | Current literature in diabetes |
Q38603504 | Current management of diabetes mellitus and future directions in care |
Q38095652 | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes |
Q47430758 | DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA1c levels: a systematic review and replication in a case-control sample of the Lifelines study. |
Q33962117 | DNA methylation of microRNA-375 in impaired glucose tolerance |
Q64082841 | DNAJB3 attenuates metabolic stress and promotes glucose uptake by eliciting Glut4 translocation |
Q38902321 | DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects |
Q42718201 | Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes |
Q87001285 | Dapagliflozin for the treatment of type 2 diabetes |
Q47871792 | Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years |
Q41641012 | Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. |
Q35578244 | Dapagliflozin lowers plasma glucose concentration and improves β-cell function |
Q46875772 | Declining ß-cell function is associated with the lack of long-range negative correlation in glucose dynamics and increased glycemic variability: A retrospective analysis in patients with type 2 diabetes |
Q37738735 | Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus |
Q90733533 | Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus |
Q34374314 | Defining and achieving treatment success in patients with type 2 diabetes mellitus |
Q38304236 | Delivery of integrated diabetes care using logistics and information technology--the Joint Asia Diabetes Evaluation (JADE) program |
Q91840038 | Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature |
Q51137844 | Design and Synthesis of Novel, Selective GPR40 AgoPAMs. |
Q43220830 | Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study |
Q50638860 | Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT. |
Q58081753 | Developing a Simple 3-Day Insulin Delivery Device to Meet the Needs of People With Type 2 Diabetes |
Q47261129 | Development and Qualification of a Drug-Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials |
Q90116085 | Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future |
Q26750829 | Diabetes Care in Venezuela |
Q38894567 | Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. |
Q35737641 | Diabetes Remission after Nonsurgical Intensive Lifestyle Intervention in Obese Patients with Type 2 Diabetes |
Q36104634 | Diabetes Susceptibility Genes Pdx1 and Clec16a Function in a Pathway Regulating Mitophagy in β-Cells |
Q38165184 | Diabetes and beta cell function: from mechanisms to evaluation and clinical implications |
Q27686977 | Diabetes and cancer: a consensus report. |
Q33959789 | Diabetes and cardiovascular disease in older adults: current status and future directions |
Q26852990 | Diabetes mellitus related bone metabolism and periodontal disease |
Q38304382 | Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease |
Q38036772 | Diabetes pharmacotherapy in 2012: considerations in medication selection |
Q37102832 | Diabetes prevention: can insulin secretagogues do the job? |
Q49833824 | Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms |
Q35785215 | Diabetes-Related Ankyrin Repeat Protein (DARP/Ankrd23) Modifies Glucose Homeostasis by Modulating AMPK Activity in Skeletal Muscle |
Q84592533 | Diabetes: Individualized therapy for diabetes mellitus--just a promise? |
Q36426827 | Diabetes: have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence |
Q35607330 | Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). |
Q58754386 | Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes |
Q92258788 | Dietary Polyphenols and Gene Expression in Molecular Pathways Associated with Type 2 Diabetes Mellitus: A Review |
Q35080426 | Dietary insulin index and insulin load in relation to biomarkers of glycemic control, plasma lipids, and inflammation markers |
Q66475531 | Dietary interventions and type 2 diabetes in youth: a fresh look at the evidence. |
Q28254308 | Dietary substitutions for refined carbohydrate that show promise for reducing risk of type 2 diabetes in men and women |
Q35607527 | Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus |
Q34392719 | Differential effects of prenatal and postnatal nutritional environment on ß-cell mass development and turnover in male and female rats |
Q37995760 | Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes |
Q42175983 | Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? |
Q38603506 | Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes |
Q37900690 | Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence |
Q37735838 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus |
Q91728002 | Discharge pharmacotherapy for Type 2 diabetic inpatients at two hospitals of different tiers in Zhejiang Province, China |
Q39779287 | Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles |
Q38066566 | Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. |
Q39731191 | Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist |
Q90403044 | Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates |
Q36473140 | Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist |
Q37322694 | Disproportionately Elevated Proinsulin Levels as an Early Indicator of β-Cell Dysfunction in Nondiabetic Offspring of Chinese Diabetic Patients. |
Q35986714 | Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction |
Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
Q37798048 | Distinctions between islet neogenesis and β‐cell replication: Implications for reversal of Type 1 and 2 diabetes |
Q37784044 | Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? |
Q38092275 | Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? |
Q92544171 | Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes |
Q87792134 | Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus |
Q43764267 | Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus |
Q37509313 | Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated |
Q38917672 | Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers |
Q38762377 | Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. |
Q35450123 | Early-life origins of type 2 diabetes: fetal programming of the beta-cell mass |
Q37413605 | Ectopic Fat Deposition on Insulin Sensitivity: Correlation of Hepatocellular Lipid Content and M Value |
Q36363419 | Effect of Anthelmintic Treatment on Insulin Resistance: A Cluster-Randomized Placebo-Controlled Trial in Indonesia |
Q35742084 | Effect of Brazilian green propolis in patients with type 2 diabetes: A double-blind randomized placebo-controlled study |
Q60572729 | Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance |
Q36716030 | Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males |
Q38913719 | Effect of aqueous extract of Aegle marmelos fruit and leaf on glycemic, insulinemic and lipidemic status of type 2 diabetic model rats |
Q51372081 | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. |
Q35060231 | Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial |
Q37119974 | Effect of glycemic control on periodontitis in type 2 diabetic patients with periodontal disease. |
Q45340364 | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial |
Q51321708 | Effect of troxerutin on insulin signaling molecules in the gastrocnemius muscle of high fat and sucrose-induced type-2 diabetic adult male rat. |
Q34726395 | Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data |
Q51370472 | Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea. |
Q48337235 | Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
Q42366423 | Effects of Incretin-Based Therapies on Diabetic Microvascular Complications |
Q34457696 | Effects of Three Low-Doses of D-Tagatose on Glycemic Control Over Six Months in Subjects with Mild Type 2 Diabetes Mellitus Under Control with Diet and Exercise |
Q58848621 | Effects of acute ingestion of whey protein with or without prior aerobic exercise on postprandial glycemia in type 2 diabetics |
Q43730588 | Effects of an outdoor bicycle-based intervention in healthy rural Indian men with normal and low birth weight |
Q37328780 | Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial. |
Q47188329 | Effects of combination of change in visceral fat and thigh muscle mass on the development of type 2 diabetes |
Q53789425 | Effects of crocin and voluntary exercise, alone or combined, on heart VEGF-A and HOMA-IR of HFD/STZ induced type 2 diabetic rats. |
Q33804747 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin |
Q34023559 | Effects of exercise training on mitochondrial function in patients with type 2 diabetes. |
Q35560576 | Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects |
Q34703169 | Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study |
Q51299858 | Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus. |
Q34024589 | Effects of the First Line Diabetes Care (FiLDCare) self-management education and support project on knowledge, attitudes, perceptions, self-management practices and glycaemic control: a quasi-experimental study conducted in the Northern Philippines |
Q51240449 | Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study. |
Q58697117 | Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis |
Q93020445 | Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen |
Q38082848 | Efficacy and safety of Jentadueto® (linagliptin plus metformin). |
Q38005020 | Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus |
Q40177955 | Efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in Korea: a multicenter, open-label, single-arm study |
Q34804900 | Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial |
Q34646948 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise |
Q26782225 | Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus |
Q31082841 | Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. |
Q36366176 | Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial |
Q48226441 | Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not contr |
Q92688509 | Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial |
Q33585786 | Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus |
Q34454269 | Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes |
Q40492085 | Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study |
Q38802437 | Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. |
Q33731748 | Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents |
Q58700185 | Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial |
Q39137878 | Elevated Fasting Plasma Glucose before Liver Transplantation is Associated with Lower Post-Transplant Survival |
Q64328753 | Elevated Levels of Alpha Cells Emanating from the Pancreatic Ducts of a Patient with a Low BMI and Chronic Pancreatitis |
Q35576497 | Elevated levels of TWEAK in skeletal muscle promote visceral obesity, insulin resistance, and metabolic dysfunction. |
Q35217463 | Emergence of insulin resistance in juvenile baboon offspring of mothers exposed to moderate maternal nutrient reduction |
Q38645792 | Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin |
Q50000790 | Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM. |
Q38638523 | Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus |
Q38863649 | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials |
Q34502358 | Empagliflozin in the treatment of type 2 diabetes: evidence to date |
Q45718198 | Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. |
Q38082465 | Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes |
Q38592327 | Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition |
Q34950492 | Enhanced lipid oxidation and maintenance of muscle insulin sensitivity despite glucose intolerance in a diet-induced obesity mouse model |
Q57471786 | Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study |
Q53678863 | Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes. |
Q91896203 | Ethnic distinctions in the pathophysiology of type 2 diabetes: a focus on black African-Caribbean populations |
Q30429072 | Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention |
Q34974105 | Etiology of insulin resistance in youth with type 2 diabetes |
Q53090753 | Evaluation and Use of Registry Data in a GIS Analysis of Diabetes. |
Q55256840 | Evaluation of Diabetogenic Mechanism of High Fat Diet in Combination with Arsenic Exposure in Male Mice. |
Q36026585 | Evaluation of Non-Laboratory and Laboratory Prediction Models for Current and Future Diabetes Mellitus: A Cross-Sectional and Retrospective Cohort Study |
Q27001226 | Evidence for DNA damage as a biological link between diabetes and cancer |
Q37368593 | Evidence for central regulation of glucose metabolism |
Q38219482 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes |
Q38908684 | Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus |
Q38726891 | Evidences for diabetes and insulin mimetic activity of medicinal plants: Present status and future prospects |
Q42798514 | Evodiamine activates AMPK and promotes adiponectin multimerization in 3T3-L1 adipocytes |
Q38828606 | Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes |
Q55338781 | Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program. |
Q36877205 | Evolution of exenatide as a diabetes therapeutic |
Q34015968 | Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition |
Q33824522 | Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes |
Q42660412 | Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes |
Q54393731 | Exercise and obesity-induced insulin resistance in skeletal muscle. |
Q33558855 | Exercise in vivo marks human myotubes in vitro: Training-induced increase in lipid metabolism |
Q30276925 | Exercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism |
Q36933850 | Exercise-like effects by Estrogen-related receptor-gamma in muscle do not prevent insulin resistance in db/db mice. |
Q51298608 | Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients. |
Q48962187 | Expression of anti-inflammatory macrophage genes within skeletal muscle correlates with insulin sensitivity in human obesity and type 2 diabetes |
Q42506140 | Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects |
Q64936598 | Faecal Microbiota Are Related to Insulin Sensitivity and Secretion in Overweight or Obese Adults. |
Q38160275 | Fasiglifam as a new potential treatment option for patients with type 2 diabetes |
Q35921374 | Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes |
Q51674195 | Fine particulate matter potentiates type 2 diabetes development in high-fat diet-treated mice: stress response and extracellular to intracellular HSP70 ratio analysis. |
Q37978206 | Fixed-dose combinations for treatment of type 2 diabetes mellitus |
Q37835612 | Focus on incretin-based therapies: targeting the core defects of type 2 diabetes |
Q36584799 | FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization |
Q38832716 | Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development |
Q89624033 | From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options |
Q93016948 | From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research |
Q45329335 | From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America |
Q38711383 | Future glucose-lowering drugs for type 2 diabetes. |
Q92649404 | GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective |
Q37974712 | GLP-1 based therapies: differential effects on fasting and postprandial glucose |
Q26858990 | GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence |
Q60044940 | GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data |
Q50786363 | GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women. |
Q42477270 | Gastric Band Surgery Leads to Improved Insulin Secretion in Overweight People with Type 2 Diabetes |
Q38616170 | Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. |
Q27026287 | Genetic and epigenetic control of metabolic health |
Q38665748 | Genetic disruption of the cardiomyocyte circadian clock differentially influences insulin-mediated processes in the heart |
Q38245418 | Genetic, nongenetic and epigenetic risk determinants in developmental programming of type 2 diabetes |
Q38101993 | Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis |
Q41255366 | Gluc-HET, a complementary chick embryo model for the characterization of antidiabetic compounds |
Q88862830 | Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes |
Q37015969 | Glucagon-like peptide-1 analogues: An overview |
Q90254074 | Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments |
Q36783849 | Glucokinase activators for diabetes therapy: May 2010 status report |
Q37921903 | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? |
Q33665283 | Glucolipotoxicity of the pancreatic beta cell. |
Q35207924 | Glucose effectiveness in obese children: relation to degree of obesity and dysglycemia. |
Q38607558 | Glucose effectiveness, but not insulin sensitivity, is improved after short-term interval training in individuals with type 2 diabetes mellitus: a controlled, randomised, crossover trial. |
Q51295248 | Glucose homeostasis after simultaneous pancreas and kidney transplantation: a comparison of subjects with C-peptide-positive non-type 1 diabetes mellitus and type 1 diabetes mellitus. |
Q34684326 | Glucose tolerance and weight loss in obese women with obstructive sleep apnea |
Q39027378 | Glycaemic and insulin responses, glycaemic index and insulinaemic index values of rice between three Asian ethnic groups |
Q40975010 | Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes |
Q34374343 | Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia |
Q35104088 | Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2 |
Q47273277 | Hepatitis B X-interacting protein promotes the formation of the insulin gene-transcribing protein complex Pdx-1/NeuroD1 in animal pancreatic β cells |
Q36801780 | Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds |
Q30583410 | Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey. |
Q43255368 | High fat and highly thermolyzed fat diets promote insulin resistance and increase DNA damage in rats. |
Q97649418 | High glucose levels increase influenza-associated damage to the pulmonary epithelial-endothelial barrier |
Q44561644 | High-intensity exercise training for the prevention of type 2 diabetes mellitus. |
Q48019532 | Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients. |
Q37682701 | How do we know if the brain is wired for type 2 diabetes? |
Q42330152 | How many oral antidiabetic drugs before insulin? |
Q41689680 | Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis |
Q37238209 | Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function |
Q26750414 | Hypoglycemic agents and potential anti-inflammatory activity |
Q36638917 | IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test |
Q45599801 | Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist |
Q34797019 | Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis. |
Q36560652 | Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach |
Q61456228 | Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents |
Q33563262 | Identification, prevalence, and treatment of painful diabetic neuropathy in patients from a rural area in South Carolina |
Q48231744 | Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass |
Q35594627 | Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study |
Q36192546 | Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study |
Q33535235 | Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus |
Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
Q47443616 | Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes |
Q90221531 | Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy |
Q47912507 | Impaired peripheral insulin sensitivity in non-obese Japanese patients with type 2 diabetes mellitus and fatty liver. |
Q39149689 | Implementing elements of a context-adapted chronic care model to improve first-line diabetes care: effects on assessment of chronic illness care and glycaemic control among people with diabetes enrolled to the First-Line Diabetes Care (FiLDCare) Pro |
Q39168097 | Implications of Resveratrol on Glucose Uptake and Metabolism. |
Q35667116 | Importance of Beta Cell Function for the Treatment of Type 2 Diabetes |
Q35095516 | Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity |
Q89059864 | Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with Type 2 diabetes |
Q42619686 | Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. |
Q38744831 | Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest? |
Q39782891 | Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists |
Q91654496 | In silico analysis of antidiabetic potential of phenolic compounds from blue corn (Zea mays L.) and black bean (Phaseolus vulgaris L.). |
Q37577126 | In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion |
Q35014728 | Inclusion of plasma lipid species improves classification of individuals at risk of type 2 diabetes |
Q37653125 | Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes |
Q34374336 | Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors |
Q35790650 | Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database |
Q51142656 | Increased circulating levels of musclin in newly diagnosed type 2 diabetic patients. |
Q35071262 | Increased gluconeogenesis in youth with newly diagnosed type 2 diabetes |
Q43620104 | Increased insulin secretion and decreased glucose concentrations, but not allostatic load, are associated with stress-related exhaustion in a clinical patient population |
Q48376266 | Increased lipid availability for three days reduces whole body glucose uptake, impairs muscle mitochondrial function and initiates opposing effects on PGC-1α promoter methylation in healthy subjects |
Q26778608 | Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors |
Q34374350 | Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus |
Q90208131 | Independent and combined effects of triglyceride-glucose index on prehypertension risk: a cross-sectional survey in China |
Q41934499 | Indexing Natural Products for Their Potential Anti-Diabetic Activity: Filtering and Mapping Discriminative Physicochemical Properties |
Q42362563 | Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know |
Q64069791 | Influences of sterol regulatory element binding protein-1c silencing on glucose production in HepG2 cells treated with free fatty acid |
Q48283389 | Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose. |
Q92635199 | Inhibition of Sodium Glucose Cotransporter 2 Attenuates the Dysregulation of Kelch-Like 3 and NaCl Cotransporter in Obese Diabetic Mice |
Q33844872 | Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
Q37449243 | Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin |
Q86057577 | Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes |
Q38065105 | Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia |
Q48140061 | Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach |
Q36637567 | Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control |
Q42145401 | Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells |
Q39334553 | Insulin Resistance and Mitochondrial Dysfunction. |
Q92650104 | Insulin Resistance in Patients With Acromegaly |
Q26740228 | Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients |
Q92436405 | Insulin at the Crossroads of Metabolic, Neurologic, and Vasculature Disease |
Q36080938 | Insulin clearance: confirmation as a highly heritable trait, and genome-wide linkage analysis |
Q35703041 | Insulin detemir for the treatment of obese patients with type 2 diabetes |
Q28079442 | Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood |
Q33959744 | Insulin inhibits cardiac contractility by inducing a Gi-biased β2-adrenergic signaling in hearts. |
Q36023488 | Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. |
Q34974110 | Insulin resistance in type 2 diabetic youth |
Q45072923 | Insulin resistance is not necessarily an essential element of metabolic syndrome. |
Q33880303 | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 |
Q34597334 | Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases |
Q37838172 | Insulin resistance: pathophysiology and rationale for treatment |
Q35688277 | Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study |
Q48142012 | Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study |
Q21135221 | Insulin sensitizing effects of oligomannuronate-chromium (III) complexes in C2C12 skeletal muscle cells |
Q83394019 | Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study |
Q44910855 | Insulin treatment of type 2 diabetes: considerations when converting from human insulin to insulin analogs |
Q46981244 | Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis |
Q51763477 | Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study. |
Q88447761 | Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One? |
Q41860557 | Insulinization: A promising strategy for the treatment of type 2 diabetes mellitus |
Q37961849 | Intensifying treatment of type 2 diabetes mellitus: adding insulin |
Q30276888 | Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease |
Q26740630 | Interactions between kidney disease and diabetes: dangerous liaisons |
Q37345367 | Interactome-transcriptome analysis discovers signatures complementary to GWAS Loci of Type 2 Diabetes |
Q35932559 | Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach |
Q36942266 | Interpreting adverse signals in diabetes drug development programs |
Q91622597 | Intra- and inter-individual metabolic profiling highlights carnitine and lysophosphatidylcholine pathways as key molecular defects in type 2 diabetes |
Q37523745 | Introduction to personalized medicine in diabetes mellitus |
Q30426407 | Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? |
Q38735419 | Investigational insulin secretagogues for type 2 diabetes |
Q92730289 | Ion channels and transporters in diabetic kidney disease |
Q38340949 | Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes |
Q38605091 | Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease? |
Q47755876 | Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. |
Q33880174 | Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis |
Q39003218 | Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? |
Q38038650 | Islet function in obese adolescents. |
Q47137951 | Jia-Wei-Jiao-Tai-Wan ameliorates type 2 diabetes by improving β cell function and reducing insulin resistance in diabetic rats |
Q64058814 | Label-free quantitation of glycated hemoglobin in single red blood cells by transient absorption microscopy and phasor analysis |
Q54245859 | Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus. |
Q42500046 | Lentivirus shRNA Grb10 targeting the pancreas induces apoptosis and improved glucose tolerance due to decreased plasma glucagon levels |
Q41661857 | Leptolide Improves Insulin Resistance in Diet-Induced Obese Mice. |
Q41369032 | Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection |
Q53097629 | Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. |
Q38078436 | Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation |
Q38108636 | Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment |
Q37573689 | Linkage of type 2 diabetes on chromosome 9p24 in Mexican Americans: additional evidence from the Veterans Administration Genetic Epidemiology Study (VAGES). |
Q55020927 | Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study. |
Q48309227 | Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. |
Q92526963 | Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease |
Q37813419 | Liraglutide in the management of type 2 diabetes |
Q34168368 | Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance. |
Q38992654 | Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management |
Q34347844 | Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus |
Q64110036 | Long-term safety and efficacy of the sodium glucose cotransporter 2 inhibitor tofogliflozin added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus (J-STEP/GLP): a 52-week open-label, multicenter, post-mar |
Q39018646 | Long-term studies of treatments for type 2 diabetes |
Q64099282 | Longevity-Associated Forkhead Box O3 (FOXO3) Single Nucleotide Polymorphisms are Associated with Type 2 Diabetes Mellitus in Chinese Elderly Women |
Q47940901 | Loureirin B promotes insulin secretion through inhibition of KATP channel and influx of intracellular calcium. |
Q30413659 | Low sensitivity of the metabolic syndrome to identify adolescents with impaired glucose tolerance: an analysis of NHANES 1999-2010. |
Q42982910 | Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study |
Q38201162 | Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport |
Q55425775 | Macrophages, meta-inflammation, and immuno-metabolism. |
Q35574560 | Management of diabetes across the course of disease: minimizing obesity-associated complications |
Q47424341 | Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness |
Q37102861 | Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes |
Q37894446 | Management of type 2 diabetes: new and future developments in treatment |
Q34332137 | Markers of tissue-specific insulin resistance predict the worsening of hyperglycemia, incident type 2 diabetes and cardiovascular disease |
Q93016700 | Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus |
Q38951163 | Mechanisms of β-cell functional adaptation to changes in workload |
Q33910549 | Metabolic characteristics of individuals at a high risk of type 2 diabetes - a comparative cross-sectional study |
Q38305698 | Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence |
Q35789001 | Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study. |
Q33858514 | Metabolic regulation by protein tyrosine phosphatases |
Q36437420 | Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes |
Q37965618 | Metformin + saxagliptin for type 2 diabetes |
Q34679569 | Metformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO System |
Q47767194 | Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer |
Q52668163 | Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. |
Q92895950 | Metformin upregulates mitophagy in patients with T2DM: A randomized placebo-controlled study |
Q37991589 | Metformin use among individuals at risk for type 2 diabetes |
Q54959769 | MicroRNA, Proteins, and Metabolites as Novel Biomarkers for Prediabetes, Diabetes, and Related Complications. |
Q35070980 | MicroRNA-494, upregulated by tumor necrosis factor-α, desensitizes insulin effect in C2C12 muscle cells |
Q47235131 | Microbial Regulation of Glucose Metabolism and Insulin Resistance |
Q91795538 | Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants |
Q85354889 | Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities |
Q37889277 | Mitochondrial pathophysiology and type 2 diabetes mellitus |
Q34407918 | Modeling type 2 diabetes in rats using high fat diet and streptozotocin |
Q38593252 | Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. |
Q33869713 | Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo |
Q64260349 | Mother or Father: Who Is in the Front Line? Mechanisms Underlying the Non-Genomic Transmission of Obesity/Diabetes via the Maternal or the Paternal Line |
Q36118363 | Mouse Models of Diabetes, Obesity and Related Kidney Disease |
Q41558135 | Multi-parameter comparison of a standardized mixed meal tolerance test in healthy and type 2 diabetic subjects: the PhenFlex challenge |
Q43080783 | Neurotrophin Signaling Is Required for Glucose-Induced Insulin Secretion |
Q38640170 | New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin |
Q38971792 | New fixed dose chemical combinations: the way forward for better diabetes type II management? |
Q42171251 | New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals |
Q90719496 | New pharmacological strategies for protecting kidney function in type 2 diabetes |
Q51605998 | New therapeutic algorithm of Type 2 diabetes: lights and shadows. |
Q36550275 | Newer antidiabetic drugs and calorie restriction mimicry |
Q38085332 | Newer insulin analogs: advances in basal insulin replacement |
Q49501260 | Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus |
Q38859044 | Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? |
Q35910421 | Novel Agents for the Treatment of Type 2 Diabetes |
Q35674683 | Novel insights into the relationship between diabetes and osteoporosis |
Q90026919 | Novel insights of elevated systemic levels of bisphenol-A (BPA) linked to poor glycemic control, accelerated cellular senescence and insulin resistance in patients with type 2 diabetes |
Q34996866 | Novel metabolic markers for the risk of diabetes development in American Indians. |
Q38259507 | Novel therapeutics for type 2 diabetes: insulin resistance |
Q38176148 | Nutritional management of type 2 diabetes mellitus and obesity and pharmacologic therapies to facilitate weight loss |
Q26825473 | Obesity and insulin resistance: an abridged molecular correlation |
Q96611949 | Obesity relates to the impairment of pancreatic β-cell function in early adulthood, independent of age at obesity onset: Findings from the santiago longitudinal study |
Q30415102 | Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions |
Q38841043 | Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile |
Q38884175 | Omarigliptin for the treatment of type 2 diabetes |
Q28287325 | Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial |
Q30498295 | Ongoing beta-cell turnover in adult nonhuman primates is not adaptively increased in streptozotocin-induced diabetes |
Q38109704 | Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy |
Q59711065 | Overfed but undernourished: recognizing nutritional inadequacies/deficiencies in patients with overweight or obesity |
Q38128788 | Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes |
Q37961846 | Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus |
Q89170110 | PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients |
Q90671184 | PDK4 Deficiency Suppresses Hepatic Glucagon Signaling by Decreasing cAMP Levels |
Q38983387 | PINK1 deficiency in b-cells increases basal insulin secretion and improves glucose tolerance in mice |
Q40214351 | PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice |
Q35532241 | PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control |
Q37992232 | PTP1B and TCPTP--nonredundant phosphatases in insulin signaling and glucose homeostasis |
Q38773844 | Pancreatic Islet Responses to Metabolic Trauma |
Q92228016 | Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function |
Q26825393 | Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block |
Q42818440 | Panorama of currently available treatments for patients with type 2 diabetes. The ADA/EASD treatment algorithm. Safety and tolerability |
Q36827593 | Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): design and methods |
Q33812448 | Pathogenesis of insulin resistance in skeletal muscle |
Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
Q35898378 | Pathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implications |
Q38188871 | Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes |
Q45933172 | Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? |
Q89027524 | Pathophysiology of Type 2 Diabetes in Children and Adolescents |
Q37505516 | Pathophysiology of prediabetes |
Q38058244 | Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. |
Q26766404 | Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR |
Q35093473 | Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study |
Q33602236 | Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study |
Q39413300 | Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum |
Q33805824 | Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach |
Q34105064 | Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes |
Q51283569 | Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients. |
Q37779779 | Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin |
Q38856808 | Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes |
Q38455771 | Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes |
Q52603694 | Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. |
Q35997284 | Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan |
Q47696671 | Pharmacological management of type 2 diabetes: what's new in 2017? |
Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
Q39170345 | Pharmacotherapy of 'treatment resistant' type 2 diabetes |
Q38835951 | Phenotypes of prediabetes and stratification of cardiometabolic risk |
Q38141219 | Physical inactivity, insulin resistance, and the oxidative-inflammatory loop |
Q38113095 | Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach |
Q47785505 | Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. |
Q34139048 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment |
Q95407683 | Pioglitazone and bladder cancer |
Q55397745 | Pioglitazone and cardiovascular risk in T2DM patients: is it good for all? |
Q37606430 | Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance |
Q37776510 | Pioglitazone: beyond glucose control. |
Q59800725 | Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases |
Q35833963 | Plasma Free Amino Acid Profiles Predict Four-Year Risk of Developing Diabetes, Metabolic Syndrome, Dyslipidemia, and Hypertension in Japanese Population |
Q91131091 | Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans |
Q38815590 | Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults. |
Q35968092 | Pleiotropic effects of incretins |
Q50988205 | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. |
Q91795502 | Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor |
Q34104455 | Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies |
Q64064432 | Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world |
Q64996887 | Post-immunotherapy new onset diabetes (PINOD)-under-recognized etiology, unexplored presentation. |
Q34219918 | Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor |
Q39775206 | Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes. |
Q28076530 | Practical combination therapy based on pathophysiology of type 2 diabetes |
Q50179665 | Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. |
Q37476370 | Prediabetes: a high-risk state for diabetes development. |
Q35109037 | Predicting the development of diabetes using the product of triglycerides and glucose: the Chungju Metabolic Disease Cohort (CMC) study |
Q51246450 | Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. |
Q37278256 | Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk |
Q64230805 | Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors |
Q34642449 | Pregnancy and the formative fifteen of diabetes |
Q36825071 | Pregnancy augments hepatic glucose storage in response to a mixed meal |
Q39796669 | Prehepatic secretion and disposal of insulin in obese adolescents as estimated by three-hour, eight-sample oral glucose tolerance tests |
Q90522399 | Prevalence of β-cell antibodies and associated autoimmune diseases in children and adolescents with type 1 diabetes (T1DM) versus type 2 diabetes (T2DM) in Qatar |
Q35686344 | Preventive pharmacotherapy in type 2 diabetes mellitus |
Q98952064 | Progesterone receptor membrane associated component 1 enhances obesity progression in mice by facilitating lipid accumulation in adipocytes |
Q38062439 | Progression of β-cell dysfunction in obese youth |
Q34894243 | Progressive hyperglycemia across the glucose tolerance continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide bioavailability. |
Q36846459 | Pronounced expression of the lipolytic inhibitor G0/G1 Switch Gene 2 (G0S2) in adipose tissue from brown bears (Ursus arctos) prior to hibernation |
Q34613391 | Protein kinase Cε modulates insulin receptor localization and trafficking in mouse embryonic fibroblasts |
Q38034083 | Proton pump inhibitors: impact on glucose metabolism |
Q37433259 | Pseudoginsenoside F11, a Novel Partial PPAR γ Agonist, Promotes Adiponectin Oligomerization and Secretion in 3T3-L1 Adipocytes |
Q35780690 | Psychological wellbeing and biochemical modulation in response to weight loss in obese type 2 diabetes patients |
Q37354187 | Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies |
Q34325851 | Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques |
Q30423718 | Racial/ethnic and sex differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents |
Q92761598 | Radiologic evidence that hypothalamic gliosis is improved after bariatric surgery in obese women with type 2 diabetes |
Q36303786 | Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). |
Q52650551 | Rapidly dissolvable microneedle patches for transdermal delivery of exenatide. |
Q33955305 | Ras inhibition induces insulin sensitivity and glucose uptake |
Q37251449 | Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. |
Q38672852 | Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes. |
Q38129805 | Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes |
Q37351709 | Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control |
Q37682555 | Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs |
Q91492192 | Real-world diabetes prevention: from theory to practice |
Q35001542 | Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment |
Q53704324 | Reduced Skeletal Muscle Phosphocreatine Concentration in Type 2 Diabetic Patients: A Quantitative Image-Based Phosphorus-31 MR Spectroscopy Study. |
Q34110159 | Reduction in inflammatory gene expression in skeletal muscle from Roux-en-Y gastric bypass patients randomized to omentectomy |
Q36830372 | Regulation of hepatic glucose uptake and storage in vivo |
Q90248124 | Relationship Between Ginsenoside Rg3 and Metabolic Syndrome |
Q48858104 | Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women |
Q41497141 | Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. |
Q57179232 | Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition |
Q64964009 | Renal function and choroidal thickness using swept-source optical coherence tomography in diabetic patients. |
Q48089786 | Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus |
Q42554440 | Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition |
Q36345951 | Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus |
Q39035951 | Renal, metabolic and cardiovascular considerations of SGLT2 inhibition |
Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
Q57817601 | Repurposing of Bromocriptine for Cancer Therapy |
Q64121402 | Resistance Exercise Training Attenuates the Loss of Endogenous GLP-1 Receptor in the Hypothalamus of Type 2 Diabetic Rats |
Q92989952 | Restricting carbohydrates at breakfast is sufficient to reduce 24-hour exposure to postprandial hyperglycemia and improve glycemic variability |
Q38113101 | Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors |
Q38442816 | Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies |
Q38751451 | Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. |
Q37251144 | Rhein protects pancreatic β-cells from dynamin-related protein-1-mediated mitochondrial fission and cell apoptosis under hyperglycemia |
Q92544129 | Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis |
Q37921905 | Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus |
Q36481193 | Role of chrysin on expression of insulin signaling molecules |
Q37566650 | Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound. |
Q47120332 | Roux-en-Y Gastric Bypass Improves Hepatic Glucose Metabolism Involving Down-Regulation of Protein Tyrosine Phosphatase 1B in Obese Rats |
Q37862878 | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. |
Q38195440 | SGLT inhibitors in management of diabetes |
Q35906490 | SGLT-2 Inhibitors: A New Mechanism for Glycemic Control |
Q88499272 | SGLT2 inhibition and heart failure-current concepts |
Q37981884 | SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. |
Q39189383 | SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus |
Q97523350 | SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control |
Q100694445 | SPARC promotes insulin secretion through down-regulation of RGS4 protein in pancreatic β cells |
Q36763213 | Safety and Efficacy of D-Tagatose in Glycemic Control in Subjects with Type 2 Diabetes |
Q31066859 | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program |
Q38395221 | Safety of antidiabetes medications: An update |
Q37963451 | Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies |
Q37982112 | Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment |
Q35411329 | Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus |
Q37973413 | Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. |
Q34239784 | Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus |
Q59575138 | Screening for insulin-independent pathways that modulate glucose homeostasis identifies androgen receptor antagonists |
Q33671491 | Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4. |
Q38071007 | Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors |
Q34562833 | Serotonin receptor 2C and insulin secretion |
Q90566414 | Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes |
Q64112606 | Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies |
Q27329865 | Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice |
Q51351374 | Sex differences in glucose and insulin trajectories prior to diabetes diagnosis: the Whitehall II study. |
Q35956851 | Sex hormone-binding globulin and type 2 diabetes mellitus |
Q47574951 | Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials |
Q42200706 | Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. |
Q51346088 | Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study. |
Q35743988 | Skeletal muscle lipid flux: running water carries no poison |
Q37406040 | Sleep apnea, sleep disturbance, and fasting glucose variability: a pilot study |
Q48244700 | Sleep duration and sleep quality are associated differently with alterations of glucose homeostasis |
Q95261292 | Sleep-disordered breathing in pregnancy: a developmental origin of offspring obesity? |
Q42696994 | Sodium glucose co-transporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline |
Q38270203 | Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes |
Q91604376 | Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus |
Q26752703 | Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence |
Q38687258 | Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences |
Q37722896 | Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale |
Q98778627 | Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus |
Q41959585 | Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions |
Q26752815 | Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin |
Q38777020 | Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes |
Q38628037 | Sotagliflozin as a potential treatment for type 2 diabetes mellitus |
Q47594287 | Statin use and risk for type 2 diabetes: what clinicians should know. |
Q28069065 | Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease |
Q37117608 | Strategies for preventing type 2 diabetes: an update for clinicians |
Q98158939 | Stress Hyperglycaemia Indicates Embolus Size and Localization in Patients with Acute Pulmonary Embolism |
Q52709053 | Structure and Function of Bone Marrow Adipocytes. |
Q90402955 | Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs |
Q38858810 | Study of the risk factors and complications of diabetes mellitus after live kidney donation |
Q34516303 | Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial |
Q91492188 | Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES) |
Q51049617 | Sugar-sweetened product consumption alters glucose homeostasis compared with dairy product consumption in men and women at risk of type 2 diabetes mellitus. |
Q45835046 | Sugars and Health Controversies: What Does the Science Say?123. |
Q53725001 | Sulforaphane ameliorates the insulin responsiveness and the lipid profile but does not alter the antioxidant response in diabetic rats. |
Q36405748 | Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. |
Q36926879 | Superiority of lipoprotein particle number to detect associations with arterial thickness and stiffness in obese youth with and without prediabetes. |
Q30405974 | Surgical treatment of type 2 diabetes: the surgeon perspective. |
Q90884287 | Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes |
Q35920736 | Synapsins I and II are not required for β-cell insulin secretion: granules must pool their own weight |
Q85111372 | Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism‐Based Model Characterizing Sodium‐Glucose Cotransporter‐2 Inhibition |
Q45388469 | Synthesis and antidiabetic activity of 2,4-thiazolidindione, imidazolidinedione and 2-thioxo-imidazolidine-4-one derivatives bearing 6-methyl chromonyl pharmacophore |
Q38224376 | Systems analysis and the prediction and prevention of Type 2 diabetes mellitus |
Q35155962 | TRAIL modulates the immune system and protects against the development of diabetes |
Q47372528 | TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. |
Q38036770 | Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin |
Q39017610 | Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. |
Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
Q34460943 | Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach |
Q37662672 | Targets and probes for non-invasive imaging of β-cells |
Q48117288 | Ten-year weight gain is associated with elevated fasting insulin levels and precedes glucose elevation |
Q24628948 | Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes |
Q58697826 | The "A to Z" of Managing Type 2 Diabetes in Culturally Diverse Populations |
Q38629197 | The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes |
Q38474070 | The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future |
Q64102562 | The Effect of Puguntano Leaf Extract (.) On P38 Mapk Levels and Glut-4 Expression in Type 2 Diabetic Rat Muscle |
Q34526790 | The Effects of Breakfast Consumption and Composition on Metabolic Wellness with a Focus on Carbohydrate Metabolism |
Q55245154 | The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. |
Q33636295 | The HMGA1-IGF-I/IGFBP system: a novel pathway for modulating glucose uptake |
Q35824137 | The Impact of Hepatitis B Vaccination Status on the Risk of Diabetes, Implicating Diabetes Risk Reduction by Successful Vaccination |
Q39294694 | The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs |
Q102060110 | The Lancet Commission on diabetes: using data to transform diabetes care and patient lives |
Q58114519 | The Pathophysiology of Gestational Diabetes Mellitus |
Q94602996 | The Pathophysiology of Type 2 Diabetes Mellitus in Non-obese Individuals: An Overview of the Current Understanding |
Q38527885 | The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? |
Q92316034 | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect |
Q26745148 | The Role of Gut Microflora and the Cholinergic Anti-inflammatory Neuroendocrine System in Diabetes Mellitus |
Q39140294 | The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy |
Q38610829 | The TZD insulin sensitizer clue provides a new route into diabetes drug discovery |
Q37652799 | The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. |
Q38680984 | The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial |
Q38602464 | The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes |
Q28511990 | The diabetes susceptibility gene Clec16a regulates mitophagy |
Q41858733 | The dirty dozen of diabetes |
Q37681206 | The disposition index: adjustment for peripheral vs. hepatic insulin sensitivity? |
Q41689708 | The dynamic plasticity of insulin production in β-cells. |
Q38793748 | The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial |
Q28588479 | The effects of propionate and valerate on insulin responsiveness for glucose uptake in 3T3-L1 adipocytes and C2C12 myotubes via G protein-coupled receptor 41 |
Q35260544 | The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials |
Q42054096 | The evolving world of GLP-1 agonist therapies for type 2 diabetes |
Q83497334 | The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease |
Q37029711 | The fractalkine/CX3CR1 system regulates β cell function and insulin secretion |
Q51013418 | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. |
Q36508961 | The importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetes |
Q38139508 | The importance of synthetic drugs for type 2 diabetes drug discovery |
Q38126109 | The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors |
Q40970126 | The law of therapeutic parsimony |
Q54408659 | The lipid peroxidation end-product and oxidant 4-hydroxynonenal induces insulin resistance in rat slow-twitch skeletal muscle. |
Q35855739 | The malnutrition of obesity: micronutrient deficiencies that promote diabetes |
Q36592820 | The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus |
Q38920983 | The power of two: an update on fixed-dose combinations for type 2 diabetes |
Q51309739 | The product of triglycerides and glucose in comparison with fasting plasma glucose did not improve diabetes prediction. |
Q38247935 | The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. |
Q90398573 | The relationship between pancreatic cancer and type 2 diabetes: cause and consequence |
Q34718244 | The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. |
Q37632127 | The renal effects of SGLT2 inhibitors and a mini-review of the literature |
Q26999933 | The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies |
Q38146960 | The role of bariatric surgery in the treatment of type 2 diabetes: current evidence and clinical guidelines |
Q37321871 | The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. |
Q89459058 | The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study |
Q37737921 | The role of physical activity in type 2 diabetes prevention: physiological and practical perspectives |
Q37940036 | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. |
Q36078949 | The thrifty phenotype hypothesis revisited |
Q92771766 | Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study |
Q37660219 | Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus |
Q37682561 | Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes |
Q64997065 | Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option? |
Q26851905 | Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention |
Q45329033 | Thiazolidinediones and clinical outcomes in type 2 diabetes |
Q42567801 | Thrombin stimulates insulin secretion via protease-activated receptor-3 |
Q60921756 | Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss |
Q60921679 | Thyroid Function in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy: A Single Center Study |
Q48092622 | Time to Glycemic Control - an Observational Study of 3 Different Operations. |
Q35076020 | Time to be cautious about prescribing sulfonylureas? |
Q42390253 | Timely insulin use: Need for social marketing |
Q45497146 | Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. |
Q33843643 | Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study. |
Q35242951 | Transcriptomic identification of ADH1B as a novel candidate gene for obesity and insulin resistance in human adipose tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES) |
Q39821664 | Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype |
Q60301930 | Treatment approach to type 2 diabetes: Past, present and future |
Q39562298 | Treatment of diabetes using traditional Chinese medicine: past, present and future |
Q26783350 | Treatment of prediabetes |
Q30384663 | Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. |
Q37258174 | Triglyceride glucose index, a marker of insulin resistance, is associated with coronary artery stenosis in asymptomatic subjects with type 2 diabetes |
Q37240257 | Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study |
Q41034697 | Triglycerides-to-HDL cholesterol ratio as screening tool for impaired glucose tolerance in obese children and adolescents |
Q42010899 | Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus |
Q92391721 | Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes |
Q92025086 | Two Cases of Successful Type 2 Diabetes Control with Lifestyle Modification in Children and Adolescents |
Q89258111 | Type 2 diabetes |
Q30404232 | Type 2 diabetes across generations: from pathophysiology to prevention and management |
Q27694430 | Type 2 diabetes can be prevented with early pharmacological intervention |
Q42171281 | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors |
Q45825323 | Type 2 diabetes in Asia: like chronic obstructive pulmonary disease, a threat to human health and wellbeing |
Q39356601 | Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden |
Q36783734 | Type 2 diabetes in youth: epidemiology and pathophysiology |
Q58447602 | Type 2 diabetes mellitus |
Q63352658 | Type 2 diabetes mellitus and osteoarthritis |
Q34620430 | Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies |
Q37837496 | Type 2 diabetes mellitus--current therapies and the emergence of surgical options |
Q37750278 | Type 2 diabetes: an expanded view of pathophysiology and therapy |
Q39061970 | Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. |
Q30431540 | Underdiagnosis of Metabolic Syndrome in Non-Hispanic Black Adolescents: A Call for Ethnic-Specific Criteria |
Q42927083 | Understanding GLP-1 Analogs and Enhancing Patient Success |
Q30240030 | Understanding and overcoming metformin gastrointestinal intolerance. |
Q61795976 | Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review |
Q90599845 | Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine |
Q33775419 | Upregulation of Tumor Necrosis Factor-α-Induced Protein 8-Like 2 mRNA Is Negatively Correlated with Serum Concentrations of Tumor Necrosis Factor-α and Interleukin 6 in Type 2 Diabetes Mellitus |
Q40153908 | Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study |
Q47700645 | Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus |
Q38599975 | Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals |
Q38587097 | User's guide to mechanism of action and clinical use of GLP-1 receptor agonists |
Q36327126 | Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety |
Q40215172 | Utility of serum lipid ratios for predicting incident type 2 diabetes: the Isfahan Diabetes Prevention Study |
Q51365759 | Validation of a multi-marker model for the prediction of incident type 2 diabetes mellitus: combined results of the Inter99 and Botnia studies. |
Q38443777 | Vegetarian Diets in the Prevention and Treatment of Type 2 Diabetes. |
Q38952609 | Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination |
Q42799850 | WSF-P-1, a novel AMPK activator, promotes adiponectin multimerization in 3T3-L1 adipocytes. |
Q35132986 | Weight Loss as a Cure for Type 2 Diabetes? Fact or Fantasy |
Q38851257 | What Have Metabolomics Approaches Taught Us About Type 2 Diabetes? |
Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
Q26786524 | What's next after metformin? focus on sulphonylurea: add-on or combination therapy |
Q33354192 | Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? |
Q47616995 | Workplace bullying and violence as risk factors for type 2 diabetes: a multicohort study and meta-analysis |
Q51350644 | XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity. |
Q52679204 | YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus. |
Q90613030 | Youth with type 2 diabetes have hepatic, peripheral, and adipose insulin resistance |
Q47108375 | Zinc Supplementation Improves Glucose Homeostasis in High Fat-Fed Mice by Enhancing Pancreatic β-Cell Function |
Q57497282 | [Metabolic control or reduction of vascular risk with current treatments. What is the priority?] |
Q21136353 | alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population |
Q51259492 | iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. |
Q88722051 | iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes |
Q42418240 | mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a Rat Model of Metabolic Syndrome |
Q36817206 | β-Cell lipotoxicity after an overnight intravenous lipid challenge and free fatty acid elevation in African American versus American white overweight/obese adolescents |
Q27692665 | β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes |
Q41395397 | β-cell function prior to liver transplantation contributes to post-operative diabetes. |
Search more.